SCCA2 as a biomarker reflecting patient‐reported disease burden in children with mild atopic dermatitis under maintenance therapy

SCCA2 reflects patient-experienced symptom burden more closely than physician-assessed severity in mild AD. Its short-term, time-dependent association with POEM suggests potential utility for identifying early or imminent symptom burden.